1,3-Butadiene (butadiene) is a potent carcinogen in mice, but not in rats. Metabolic studies may provide an explanation of these species differences and their relevance to humans. Male SpragueDawley rats and B6C3F1 mice were exposed for 6 h to 200 ppm [2,3-14 C]-butadiene (specific radioactivity [sa] 20 mCi/mmol) in a Cannon nose-only system. Radioactivity in urine, feces, exhaled volatiles and 14 C-CO 2 were measured during and up to 42 h after exposure. The total uptake of butadiene by rats and mice under these experimental conditions was 0.19 and 0.38 mmol (equivalent to 3.8 and 7.5 mCi) per kg body weight, respectively. In the rat, 40% of the recovered radioactivity was exhaled as 14 C-CO 2 , 70% of which was trapped during the 6-h exposure period. In contrast, only 6% was exhaled as 14 C-CO 2 by mice, 3% during the 6-h exposure and 97% in the 42 h following cessation of exposure. The formation of 14 C-CO 2 from [2,3-14 C]-labeled butadiene indicated a ready biodegradability of butadiene. Radioactivity excreted in urine accounted for 42% of the recovered radioactivity from rats and 71% from mice. Small amounts of radioactivity were recovered in feces, exhaled volatiles and carcasses. Although there was a large measure of commonality, the exposure to butadiene also led to the formation of different metabolites in rats and mice. These metabolites were not found after administration of [4-14 C] -1,2-epoxy-3-butene to animals by ip injection. The results show that the species differences in the metabolism of butadiene are not simply confined to the quantitative formation of epoxides, but also reflect a species-dependant selection of metabolic pathways. No metabolites other than those formed via an epoxide intermediate were identified in the urine of rats or mice after exposure to 14 C-butadiene. These findings may have relevance for the prediction of butadiene toxicity and provide a basis for a revision of the existing physiologically based pharmacokinetic models.
Epidemiological studies suggest that occupational exposure of workers in the styrene-butadiene rubber industry may be associated with an increased incidence of lymphatic and hematopoietic cancers (Acquavella, 1996; Delzell et al., 1996; Divine and Hartman, 1996) , but these retrospective cohort studies are difficult to interpret. The use of animal data to support the human risk assessment of 1,3-butadiene (butadiene) is confounded by the large variation in the response that has been observed between experimental species. Low levels of butadiene caused cancer in several organs in B6C3F1 mice, whereas tumors in Sprague Dawley rats were only seen after exposure to higher concentrations of 1000 ppm (NTP, 1984 (NTP, , 1993 Owen, 1981; Owen et al., 1987; Owen and Glaister, 1990) . For example, lung tumors were observed in female mice after exposure to 6 ppm butadiene, and hemangiosarcomas of the heart after exposure to 20 ppm. Induction occurred after only 13 weeks of exposure to butadiene at concentrations of 625 ppm in mice. Thus, mice are considerably more sensitive (Ͼ100-fold) to butadiene than rats. In addition, rats do not develop the same pattern of tumor types even at the very high concentrations. The toxicology and epidemiology of butadiene have recently been comprehensively reviewed (Himmelstein et al., 1997) .
The debate over whether butadiene is a human carcinogen under normal conditions of use has driven research into the mechanisms of butadiene carcinogenesis and the extrapolation of results from animals to man. In-vitro experiments and mathematical, physiologically based pharmokinetic (PBPK) models have been used (Evelo et al., 1993; Johanson and Filser, 1993; Kohn and Melnick, 1993; Sweeney et al., 1997) . The underlying principle is that butadiene is converted to reactive metabolites, which in turn are responsible for the observed carcinogenicity. Previous studies have shown that butadiene is metabolized to the monoepoxide, 1,2-epoxy-3-butene (butadiene monoepoxide, BMO) and its diepoxide, 1,2,3,4-diepoxybutane (Bolt et al., 1983; Csanàdy et al., 1992; Malvoisin et al., 1979; Malvoisin and Roberfroid, 1982; Himmelstein et al., 1995 Himmelstein et al., , 1994 Schmidt and Loeser, 1982; Thornton-Manning et al., 1995a,b) . These epoxides have a potential of reacting with biomolecules and thus have been implicated in the carcinogenic response. Butadiene diepoxide is seen as a highly sig-nificant metabolite, which is up to 100-fold more mutagenic than BMO in-vitro (Cochrane and Skopek, 1994) and has been shown to be responsible for DNA cross-links (Millard and White, 1993) .
It has been suggested that differences in the ability to produce and detoxify these epoxides via enzyme-catalysed hydrolysis and conjugation with glutathione (GSH) determine the susceptibility of the animal to butadiene-induced carcinogenesis (ECETOC, 1993; Himmelstein et al., 1997) . Comparative data from in-vitro studies indicates that humans possess a reduced ability to produce butadiene monoepoxide and butadiene diepoxide and an increased ability to detoxify them via enzyme-mediated hydrolysis. Thus, human susceptibility towards butadiene carcinogenesis is expected to be significantly lower than that of the mouse. But these results do not explain why mice developed tumors at exposure concentrations as low as 6 ppm, while tumors were not found in rats at 8000 ppm, even though butadiene monoepoxide accumulating in the rat at this dose level exceeds that in the mouse at 6 ppm. Furthermore, recent publications describing PBPK models developed on the basis of the kinetics of epoxide formation and detoxification, in vitro, do not predict actual observed levels of butadiene monoepoxide or butadiene diepoxide obtained in rats and mice after exposure to butadiene (Sweeney et al., 1997 and references therein) . Better data fits were obtained when it was assumed that butadiene metabolism proceeded through an additional pathway, not via butadiene monoepoxide as an intermediate (Sweeney et al., 1997) .
The possibility of a metabolic pathway involving acrolein or crotonaldehyde has been proposed based on in-vitro experiments (Cheng and Ruth, 1993; Duescher and Elfarra, 1994; Elfarra et al., 1991; Sharer et al., 1992) and the NMR analysis of metabolites in urine from rats and mice exposed to carbon-13-labelled butadiene (Nauhaus et al., 1996) . These publications have highlighted the potential for metabolic pathways other than the established butadiene monoepoxide and diepoxide routes, with the suggestion that these may contribute to differences in sensitivity. However, the significance of these pathways, if they exist, has not been determined.
Clearly, a detailed understanding of metabolic fate is an essential component in the risk assessment of butadiene. The objective of the current study was to obtain a more complete picture of the metabolism and distribution of 14 C-butadiene and its metabolites in rats and mice during and following inhalation exposure.
14 C-Butadiene was employed at a high specific radioactivity (sa 20 mCi/mmol) to enable exposure to a relatively low concentration of 200 ppm. This exposure is within the range for the development of tumors in male mice, and is below the no-observed-effect level (NOEL) of 1000 ppm in the rat. A single exposure concentration was chosen in this study for practical reasons, the concentration selected being below the saturation level for these species. Studies to investigate the effect of concentration in the low-dose-exposure range are in progress to determine whether there are effects on metabolism caused by changes in concentration of butadiene.
MATERIALS AND METHODS
Safety. 1,3-Butadiene (CAS No. 106 -99 -0) is extremely flammable, toxic, and a known animal carcinogen. All work with the chemical should be conducted in a well-ventilated fume hood while wearing protective clothing.
Chemicals. Unless otherwise stated, chemicals were of the highest available purity. Solvents used for HPLC were HPLC grade. All solvents used for other purposes were analytical grade. Tetraethylammonium hydroxide (TEAH) was a gift from Shell International Chemicals, Zaltbommel, The Netherlands. 3-(N-Acetylcystein-S-yl)-propan-1-ol was a gift from Dr. J. Kehrer, College of Pharmacy, University of Texas at Austin (Ramu et al., 1995) . The reference chemicals:
ene, and 4-(N-acetyl-L-cystein-S-yl)-1-hydroxybut-2-ene and 4-(N-acetylcystein-S-yl)-1,2,3-trihydroxybutane were synthesized as previously described . Samples of urine obtained from treatment of rats and mice with 14 C-butadiene monoepoxide and containing fully characterized 14 C-labelled metabolites were also available to facilitate identification .
Radiochemical synthesis. [2,3-
14 C]-Butadiene (sa 20.1 mCi/mmol; 14 Cbutadiene, Fig. 1 ) was synthesised from 1,2-dibromo-[1,2-14 C]-ethane by a method developed at Amersham International Plc., UK.
14 C-Butadiene was purified by distillation and the radiochemical purity was established by the vendor as 98.7%, using radio-GC and co-chromatography with commercially available material. The GC/MS spectrum gave ions at m/z: 54 and 58 consistent with the molecular weight of butadiene containing two 14 C-labelled carbons. The molecular weight at the sa given was 54.7 g/mol.
14 C-Butadiene was supplied as a gas under atmospheric pressure in 4 borosilicate glass, break-seal, round-bottom ampoules (250 ml) containing 135 mCi of radioactivity each and stabilized with 4-t-butylcatechol (100 ppm). Studies indicated that the 14 C-butadiene was stable for at least 7 days at room temperature under these conditions. The 14 C-butadiene was kept at room temperature during storage and shipment and was not cooled at any time. On the day of each inhalation exposure, the purity of butadiene was determined by IR and on-line analysis (see sections Inhalation exposure of rats and mice/Generation of exposure atmosphere).
Synthesis of reference standards
3-(N-Acetyl-L-cystein-S-yl)-3-methylpropanoic acid. Crotonic acid (172.2 mg, 2.0 mmol) was added to a solution of N-acetyl-L-cysteine (NAC, 326 mg, 2.0 mmol) in water (2 ml). The resulting mixture was heated at 65°C for 72 h. NMR indicated that 3-(N-acetyl-L-cystein-S-yl)-3-methylpropanoic acid was formed in ϳ40% yield, the remainder being unreacted crotonic acid and NAC. The mixture was not further purified, since sufficient product was present for conversion to the dimethyl ester derivative.
1 H-NMR (200 MHz, CD 3 OD): 4.6 -4.5 (1H, m, CHmethine); 3.4 -2.9 (3H, m, CH 2 S and SCH); 2.64 -2.58 (2H, dAB, J ϭ 7.1 Hz, CH 2 CO 2 H); 2.04 (3H, s, COCH 3 ); 1.32 and 1.29 (3H, d, J ϭ 2Hz, CH 3 ).
3-(N-Acetyl-L-cystein-S-yl)-3-methylpropanoic acid dimethyl ester.
A small subsample (1 mg) of the unpurified 3-(N-acetyl-L-cystein-S-yl)-3-meth-
FIG. 1. [2,3-
14 C]-1,3-Butadiene (*denotes position of radio-label).
ylpropanoic acid was dissolved in methanol/HCl (1 ml, prepared by addition of acetyl chloride (1 ml) to methanol (10 ml)), and heated at 60°C for 1 h. The reaction was allowed to cool and the solvent to evaporate to dryness at 40 -50°C under nitrogen. The sample was re-dissolved in toluene (100 l) for analysis. GC/MS under EI conditions afforded ions at m/z: 277 (M ϩ. ), 218 (M-59, base peak), 204, 186, 176, 153, 144, 117, 101, 88, 69, 59, and 43 corresponding to the spectra previously reported (Onkenhout et al., 1982) .
3-(N-Acetyl-L-cystein-S-yl)-2-oxopropanoic acid ethyl ester. A solution of sodium hydroxide (220 mg, 5.5 mmol) in de-ionized water (1.38 ml) was added to a mixture of N-acetyl-L-cysteine (492 mg; 3.0 mmol) in methanol (5.0 ml). The pH of the solution was 9 -10. Bromopyruvate (650 mg; 3.0 mmol) was dissolved in methanol (2.0 ml) and added drop-wise to the reaction mixture. The mixture was stirred overnight at 60 -61°C. The pH of the brown-colored solution was 3. TLC (ethyl acetate:hexane, 1:1, v/v) indicated the majority of bromopyruvate had reacted. Methanol was removed at reduced pressure at 45°C and ethyl acetate (10 ml) and water (10 ml) were added. After vigorous stirring, the organic layer was separated and washed with water (10 ml), dried over magnesium sulphate and concentrated under reduced pressure. The oily residue was treated with chloroform to remove residual bromopyruvic acid ethyl ester. The mixture was not further purified, since sufficient product was present for conversion to the dimethyl ester derivative.
1 H-NMR (200 MHz, CD 3 OD: 4.7-4.5 (1H, m, CH-methine); 4.3-4.2 (2H, m, OCH 2 ); 3.9 -3.7 (2H, m, SCH 2 CO); 3.2-3.0 (2H, m, CH 2 S); 2.1 (3H, s, COCH 3 ); 1.4 -1.2 (3H, m, OCH 2 CH 3 ).
3-(N-Acetyl-L-cystein-S-yl)-2-oxopropanoic acid dimethyl ester. A small subsample (1 mg) of the unpurified 3-(N-acetyl-L-cystein-S-yl)-2-oxopropanoic acid ethyl ester was dissolved in methanol/HCl (1 ml, prepared by addition of acetyl chloride (1 ml) to methanol (10 ml)) and heated at 60°C for 1 h. The reaction was allowed to cool and the solvent was evaporated to dryness at 40 -50°C under nitrogen. The sample was re-dissolved in toluene (100 l) for analysis. GC/MS under EI conditions showed 3-(N-acetyl-Lcystein-S-yl)-2-oxopropanoic acid dimethyl ester via transesterification as the major product which afforded ions at m/z: 277 (M ϩ. ), 218 (M-59), 207, 176, 158, 144, 134, 117, 101, 88, 74, 60, and 43 (base peak) .
Inhalation exposure of rats and mice. Inhalation exposures of rats and mice were conducted at CIIT as a collaborative study between CIIT and the Toxicology Department, Shell Research and Technology Centre Amsterdam. Male Sprague Dawley rats (400 g, 12 weeks) and male B6C3F1 mice (30 g, 12 weeks) were purchased from Charles River Labs (Raleigh, NC) and were housed according to recommendations listed in the guide for care and use of laboratory animals (DHEW, 1986) allowing acclimatization for approximately 14 days. Animals were supplied food (NIH 07 diet) and deionized water ad libitum, except during exposure to 14 C-butadiene, and maintained on a 12-h light-dark cycle at a temperature of 22 Ϯ 2°C and relative humidity of 55 Ϯ 5%.
Male SD rats (12 animals) and male B6C3F1 mice (50 animals) were exposed on separate occasions to 200 ppm 14 C-butadiene for 6 h using a modified Cannon (Cannon et al., 1983) nose-only exposure system (Lab products, Maywood, NJ) constructed from inert materials (stainless steel with Teflon delivery lines). In this exposure system, the atmosphere flows through a central plenum with outlet tubes that direct the atmosphere past the nose of each animal preventing rebreathing of exhaled air. To minimize the amount of 14 C-butadiene required, the flow through the nose-only system was held to a minimum recommended flow rate of 1.5 times the animal minute ventilation (Cheng and Moss, 1995) . A minute ventilation of 250 ml/min for rats and 45 ml/min for mice was used for calculations based on reported literature values (Bond et al., 1986) . The total radioactivity required was 268 mCi for the rat study and 201 mCi for the mouse study. For reasons of safety and well being of animals, the Cannon tower was placed in an 8 m 3 chamber kept at a temperature between 19 and 21°C and a relative humidity of 50%. The Cannon tower tubes in which the animals were placed were modified to allow the separate collection of urine and feces, which enabled the separate determination of radioactivity excreted during exposure. The exhaust from the tower was filtered through 2 charcoal traps to absorb radioactivity not retained by the animals. The cartridges were placed in parallel with a set of plug valves to allow switching from one cartridge to the other without altering the exhaust flow. After filtering through the charcoal traps, the exposure atmosphere was partially diverted (500 ml/min) to alkaline traps (3 traps in series) for the subsequent collection of 14 C-CO 2 . Alkaline traps were periodically changed during exposure at 2, 4, and 6 h after the beginning of the exposure.
Generation of exposure atmosphere. The ampoule containing 14 C-butadiene was opened by forcing a stainless steel tube through the break-seal joint via a T-connector to which a septum and a bag delivery line were connected. The contents of the ampoule were transferred into a Tedlar bag (SKC, Inc., Eighty Four, PA) using a measured volume of nitrogen gas. The bag was allowed to stand until the gas concentration was homogenous throughout the bag. The concentration of this stock vapor was determined by sampling (10 l) from a septum attached to the Tedlar bag, using a gas-tight syringe. Samples were injected into Ecolume (ICN, Costa Mesa, CA) for scintillation counting (Packard Tri-Carb scintillation Counter, 1900CA). Since the radiochemical was delivered in 4 separate containers, 2 separate bags were prepared for each exposure. Once it had been determined that the concentration of radioactivity in the bag had equilibrated, the 14 C-butadiene was mixed with air to achieve a total flow of 4.4 l/min through the Cannon tower. The concentration of the mixture was continuously monitored before entering the exposure system by an on-line IR spectrophotometer (MIRAN, Foxoboro, MA) calibrated by a closed loop technique with unlabeled butadiene. The butadiene exposure atmosphere was also analyzed using a gas chromatograph (Model 5880, Hewlett-Packard, Palo Alto, CA) equipped with a flame ionization (FID) and a radioactivity detector (GC-RAM, In/Us, Inc., Fairfield, NJ). A multiport sampling valve was used to sample the inlet to the nose-only chamber, the outlet of the chamber, and after the filtered exhaust (to monitor for breakthrough).
Metabolism studies. Immediately after the 6-h exposure, 3 rats and 5 mice were transferred to gas-tight individual rat and mouse metabolism cages. Urine and feces were collected over solid-CO 2 for 0 -6, 6 -24, and 24 -42 h following exposure. Radioactivity in samples was quantified by scintillation counting and oxygen combustion as described below. The expired air from each cage was drawn by a vacuum pump at a rate of 500 ml/min for rats and 200 ml/min for mice through a series of 3 charcoal filters (Supelco ORBO, 0.9 g) to determine exhaled organic volatiles ( 14 C-butadiene and 14 C-metabolites) and subsequently through a KOH solution (1 M, 450 ml for rats and 200 ml for mice) for the determination of 14 C-CO 2 . Traps for volatiles and 14 C-CO 2 were changed at intervals 1, 3, 6, 24, and 42 h after the 6-h exposure period and analyzed as described below. For the collection of larger urine volumes necessary for metabolite isolation and identification, 2 additional rats and 3 groups of 5 mice each were housed in perspex cages equipped for the separate collection of urine and feces and placed in fume hoods. Mice were housed in rat cages with adapted grids and food hoppers. Control animals were placed in perspex metabolism cages and urine and feces were collected 0 -6 h, 6 -24 h, and 24 -42 h after exposure, as for exposed animals.
Urine and feces collected from the Cannon-tower and metabolism cages and charcoal traps for exhaled volatiles were transferred to glass tubes, sealed and stored individually at Ϫ80°C until transport and further analysis.
Tissue distribution of radioactivity. At the end of the 42-h collection, animals were removed from the metabolism cages and given a lethal dose of sodium pentobarbital and heparin by ip injection. Blood samples were taken by cardiac puncture from 4 rats and 18 mice. Following confirmed death, tissues (lung, liver, thymus, heart, fat, testes, kidneys, adrenal glands, spleen, muscle, femoral bone marrow, brain, gastrointestinal tract, and soft abdominal tissue) were removed, weighed and stored at Ϫ80°C until further analysis. In addition, 7 rats and 6 groups of 5 mice were sacrificed immediately after exposure to 200 ppm 14 C-butadiene for the collection of blood and tissues. Before dissection, urine was removed from the bladders using a syringe, and stored at Ϫ80°C for analysis of metabolites.
Autoradiography. One rat and 2 mice received lethal doses of anaesthetic as described, about 42 h after the termination of exposure. Following confirmed death, the carcasses were frozen in a mixture of hexane and excess solid-CO 2 and then stored at Ϫ20°C until analysis. The frozen carcasses were set in blocks of aqueous carboxymethylcellulose (2% w/v) and sectioned, longitudinally (30 m thickness), using a cryomicrotome maintained at about Ϫ20°C. Sections were obtained from 5 different levels to expose a range of smaller tissues which could not be easily dissected, such as central nervous system and glandular organs. The distribution of radioactivity in the sections was measured using a radioluminography system (Fuji BAS 1500, Raytek Scientific Ltd, UK). Quantitation was obtained by comparison with standards. Preparation and sectioning of the frozen carcasses and the quantitative wholebody autoradiography measurements were conducted at Covance Laboratories (Harrogate, UK).
Quantitation of radioactivity. Liquid samples (2ϫ 10 -100 l) were taken up in Optiphase Safe (LKB) or Ultima Gold scintillation fluid (CanberraPackard) and measured using a Canberra-Packard (model 2200CA) liquid scintillation counter. Radioactivity in blood, tissue and feces was determined by oxygen combustion using a Canberra-Packard 306M combustor. Duplicate or triplicate samples of ϳ100 -200 mg were analyzed except for whole blood, bone marrow, adrenal glands, and fat where ϳ25-50 mg samples were used. The combustion efficiency was determined using commercial standards (Amersham) or control tissues spiked with carbon-14 standard (Canberra-Packard). Carcasses were solubilized in TEAH/ethanol solution (20%, v/v) and the radioactivity in duplicate aliquots (1 ml) was measured by liquid scintillation counting (LSC). Charcoal filters were analyzed for radioactivity by emptying the charcoal from the filter into a conical centrifuge tube and adding dimethylformamide (DMF, 2 ml). After mixing, the charcoal was pelleted by centrifugation (Jouan CR3000 centrifuge, 3000 rpm, 5 min) and the supernatant removed. Aliquots (2ϫ100 l) of supernatant were analyzed for radioactivity by scintillation counting. Alternatively, subsamples of charcoal (200 mg) were analyzed by oxygen combustion as described above. The radioactivity in the KOH trap solutions containing exhaled 14 C-CO 2 was measured by LSC. Duplicate aliquots (1 ml) were added to pre-weighed scintillation vials (20 ml) containing distilled water (5 ml) to which scintillation fluid (14 ml) was added before counting.
Identification of urinary metabolites. Metabolite profiles were obtained by reverse phase HPLC (YMC ODS-5 m column, 250 ϫ 4.6 mm) and on-line radioactivity detection (Ramona 90, solid cell, Raytek Scientific, Ltd, Sheffield, UK). The column was eluted with 1 mM ammonium formate buffer, pH 3 (prepared by the addition of 3.8 ml formic acid, diluted with water to 1l, to 10 ml 0.1 M ammonium formate) containing 9% acetonitrile at a flow rate of 1 ml/min. Metabolites were identified by co-chromatography, with reference samples prepared chemically, or obtained from rat and mouse urine after dosing with 14 C-butadiene monoepoxide . The structures of the metabolites were confirmed by liquid chromatography (LC) with mass spectrometry (MS) of the urine sample. When further proof of identity was required, metabolites were isolated from urine. The isolated fractions were analyzed by LC/MS, LC/MS/MS or derivatized and analyzed by gas chromatography (GC) with on-line MS.
Enzymatic treatment of urine. Aliquots of urine (rat, 0.5 ml, mouse, 0.2 ml) were diluted with an equal volume of ammonium acetate buffer (0.2 M), pH 5.0 and incubated with an equal volume of glucurase (␤-glucuronidase 5000 units/ml, ex. bovine liver, Sigma) or sulphatase (0.64 mg, Type H-1, ex Helix pomatia, 18,000 units/g, Sigma) or acylase I (6 mg, 7000 units/mg, Sigma) overnight at 37°C. The reaction was stopped by cooling to Ϫ20°C. Metabolic profiles were analyzed by radio-HPLC and compared to those of control samples incubated without enzyme. The activity of the sulphatase and glucuronidase enzymes was checked by the addition of p-nitrophenyl sulphate or phenolphthalein glucuronic acid (Sigma) after overnight incubation. After a further 30 min, sodium hydroxide (1.0 M, 0.5 ml) was added and the development of a yellow (p-nitrophenol) or pink (phenolphthalein) color indicated the viability of the enzymes.
Isolation of urinary components. Combined urine samples from individual rats and mice collected from metabolism cages 0 -6 h, 6 -24 h and 24 -42 h after butadiene exposure were fractionated by using preparative reverse phase HPLC (YMC ODS AQ-5 m column, 250 ϫ 20 mm). The column was eluted with 1 mM ammonium formate buffer, pH 3, containing 9% acetonitrile at a flow rate of 10 ml/min. Fractions were freeze dried and reconstituted in methanol/water. To verify purity, and when necessary to achieve further separation, fractions were re-analyzed by analytical reverse phase HPLC as described above, but using varying amounts of acetonitrile (1-9%) depending on the polarity of the fraction.
Chemical derivatization of reference chemicals and metabolites. Samples of reference chemicals or isolated metabolite fractions were evaporated to dryness at 30 -40°C under nitrogen, redissolved in dry acetonitrile (50 l) and again evaporated to dryness. Dry samples of isolated metabolite fractions were methylated by addition of methanol/HCl (acetyl chloride, 1 ml, in methanol, 10 ml) and heating at 60°C for 1h. Samples were cooled, evaporated to dryness at 40 -50°C under nitrogen, and dissolved in ethyl acetate for analysis. A fraction of the methylated product was acetylated by adding acetic anhydride/triethyl amine/acetone (1:2:5 v/v/v) and heating at 60°C for 15 min. After cooling and evaporation to dryness at 40 -50°C under nitrogen, derivatized metabolites were dissolved in ethyl acetate and analyzed by GC/MS. GC/MS of reference chemicals and urine metabolites. GC (Hewlett Packard 5890 series II) of derivatized samples used an HP-5 column (Hewlett Packard, 25 m ϫ 0.32 mm, 1.05 m film thickness), on-column injection, and helium as a carrier gas at a flow rate of 1 ml/min. The initial oven temperature was 80°C. After 1 min, the temperature was increased at a rate of 40°C/min to 250°C. The flow was split 10 to 1 to on-line MS (Hewlett Packard MSD 5971A). The radioactivity in the remainder of the flow was mixed with helium (2.5 ml/min) and hydrogen gas (4 ml/min) and measured using an RAGA 90 detector in reducing mode, with methane (35 ml/min) as a counting gas. The combination of radioactivity detection with MS analysis ensured the correct selection of metabolites in samples which contained multiple components. For further identification, derivatized samples were analyzed using GC coupled to a Hewlett Packard Engine MS5989B operating in either electron impact or negative chemical ionization (methane/argon) mode. Data was acquired with a Hewlett Packard G1034C Chemstation operating with version C.03.00 software. A DB-5 column (30 m or 60 m ϫ 0.25 mm, 0.25 m film thickness) was used with split/splitless (240°C) injection. The initial oven temperature was 40°C. After 1 min, the temperature was increased at a rate of 20°C/min to 220°C.
LC/MS of reference chemicals and urine metabolites standards. Reference chemicals or 14 C-butadiene metabolites in whole urine and isolated fractions were separated by reverse phase HPLC, using a YMC ODS AQ column (250 ϫ 4.6 mm, 5 m) eluting with 1 mM ammonium formate buffer, pH 3, containing acetonitrile (9%) at a flow rate of 1 ml/min. The flow was split to 150 l/min for mass spectrometry (VG Quattro triple quadrupole, Electrospray Ionisation, using a source temperature of 100°C and a cone voltage of 20 eV). The remainder of the flow was monitored by a flow-through radiodetector (Ramona 90).
NMR analysis of reference chemicals and metabolites.
1 H-NMR spectra of synthetic reference chemicals were measured on a Varian Gemini 200 MHz machine. 13 C-NMR spectra of reference chemicals were measured on a Bruker AC 250 MHz machine.
1 H-NMR spectra of isolated metabolite fractions (ϳ50 g dissolved in 350 l D 2 O) were recorded on a Bruker DRX-500 spectrometer (11.7 Tesla) employing a 2.5-mm dual micro-probe head and a 90°proton pulse of 5.3 s (512 scans, delay between scans, 2 s) at 288 or 298 K. The HDO peak was suppressed by pre-saturation. Molecular structures were confirmed by 2-D Total Correlation Spectroscopy (TOCSY), using an MLEV17 sequence for mixing (Bax and Davis, 1985) and a mixing time of 9 ms to provide information on strong, short-range proton coupling.
RESULTS

Generation of Exposure Atmosphere
Exposure concentrations were within 90% of the target concentration of 200 ppm during the course of the exposure (averaging 201 Ϯ 21 ppm for rats and 201 Ϯ 13 ppm for mice) and 95% of the target 6-h exposure time (5 h 46 min for rats and 5 h 43 min for mice). The purity of the 14 C-butadiene as determined by IR was Ͼ99%.
Animal Observations
No signs of toxicity were observed in rats and mice immediately after receiving 14 C-butadiene. Animals were damp after inhalation exposure, either from urine or humidity of the air, but appeared otherwise well. All animals appeared healthy and were eating and drinking normally during the 42-h holding period in metabolism cages.
Total Dose Received
The total uptake of radioactivity by animals exposed for 6 h to 200 ppm 14 C-butadiene by inhalation was 1518 Ϯ 119 Ci per rat and 225 Ϯ 7 Ci per mouse. These totals were calculated by summation of the radioactivity in urine, feces, organic volatiles, and 14 C-CO 2 collected during and after exposure, and the radioactivity remaining in tissues and carcasses 42 h after exposure. Volatiles exhaled during exposure were trapped, but their nature could not be determined due to the high amount of 14 C-butadiene present from the exposure atmosphere. Based on the average body weight of rats (0.4 kg) and mice (0.03 kg), the uptake for rats was 3796 Ci/kg and for mice was 7514 Ci/kg, equivalent to doses of 14 C-butadiene of 10 mg/kg and 21 mg/kg for rats and mice, respectively. Thus, when exposed to a similar concentration of 14 C-butadiene, the uptake by mice was approximately twice as much of the radioactivity per kg body weight as by rats. Based on minute volumes of 250 ml/min and 45 ml/min for rats and mice, respectively, the radioactivity in air inhaled during the 6-h inhalation exposure to 200 ppm 14 C-butadiene was 14625 Ci for rats and 2633 Ci for mice. Thus, the radioactivity retained and processed 
Note. n, 5 for rats and mice. Percentage uptake of butadiene is shown in parentheses. a nd, not determined. Exhaled organic volatiles could not be determined during exposure in the nose-only inhalation system, since they could not be distinguished from the 14 C-butadiene in the exposure atmosphere. b Equivalent to 3796 Ci/kg using an average body weight of 400 g c Radioactivity recovered in the Cannon Tower feces was heavily contaminated with urine and therefore included in the urinary recoveries for further calculations.
d Equivalent to 7514 Ci/kg using an average body weight of 30 g.
accounted for 10% and 9% of the total radioactivity inhaled from the exposure atmosphere per rat and per mouse respectively.
Excretion of Radioactivity
A summary of the excretion of radioactivity is given in Table 1 . Radioactivity in the urine accounted for 42% of the butadiene processed by rats and 71% processed by mice. The urinary elimination was rapid and essentially complete 42 h after cessation of exposure, with the greatest proportion excreted in the first 6 h after termination of the exposure. In the rat, 9% of the radioactivity was excreted in the urine during inhalation exposure, with a further 23% in the first 6 h after dosing and 8% in the following period (6 to 24 h). Only 1% of radioactivity was recovered in the urine between 24 h and 42 h. In mice, 6% of the radioactivity was recovered in the urine during exposure, 42% in the 0 -6 h after exposure, 9% in the 6 -24 h period after exposure and a small amount (6%) in the following 24 -42 h. Recoveries in cage washes 42 h after dosing accounted for less than 2% of the radioactivity and were included in the urinary recoveries. A small fraction of the radioactivity was recovered in the feces of rats (8%) and mice (11%). Some contamination of feces with urine may have occurred, especially for mouse feces recovered from the Cannon-tower, and these were therefore included in the urinary recoveries.
Major differences between rat and mouse were seen in the 14 C-CO 2 produced and in the time-courses of 14 C-CO 2 exhalation (Figs. 2 and 3) . In the rat, a major part of the radioactivity was exhaled as 14 C-CO 2 (40%), while this was only a minor amount in mice (6%). In the rat, the principal proportion (70%) of 14 C-CO 2 (equal to 28% of the dose of butadiene) was excreted during the 6-h inhalation-exposure period. The exhalation reached a plateau after cessation of exposure, with 9% of the dose of butadiene exhaled as 14 C-CO 2 during 0 -6 h after exposure and a further 3% between 6 and 24 h. Only 1% of the radioactivity was exhaled as 14 C-CO 2 between 24 h and 42 h. This indicated that the exhalation of 14 C-CO 2 in the rat was very rapid and essentially complete 42 h after cessation of the inhalation exposure. In mice, only a small proportion of the radioactivity (0.2% of the dose of butadiene) exhaled as 14 C-CO 2 was recovered during the exposure period. In the 0 -6 h period after cessation of exposure, the radioactivity recovered as 14 C-CO 2 from mice accounted for 4% of the dose of butadiene, 1% in the 6 -24 h period after exposure and 0.4% in the following 24 -42 h.
Exhaled organic volatiles accounted for a minor part of radioactivity exhaled by both rats (2%) and mice (0.2%). In the Cannon-tower set-up, the 14 C-butadiene exhaled by the animals during exposure and possible other volatile metabolites (e.g., 14 C-butadiene monoepoxide) were trapped onto charcoal, together with unchanged 14 C-butadiene in the exposure atmosphere, and could therefore not be distinguished from 14 Cbutadiene from the exposure atmosphere, or quantified. Loss of volatile metabolic products potentially formed from butadiene, such as acrolein or crotonaldehyde, was not expected. When acrolein is administered by iv injection, only a small proportion of the dose (0.2-0.3%) is exhaled as the parent compound (Parent et al., 1996) .
At the end of the holding period in metabolism cages (42 h after termination of exposure), 9% of butadiene metabolized by rats and 13% metabolized by mice were associated with the carcasses and tissues. 
Tissue Distribution of Radioactivity
A summary of the tissue distribution of radioactivity at 0 h and 42 h after termination of the inhalation exposure is given in Table 2 . Radioactivity in blood was higher in the mouse (107 nmol/g) than the rat (81 nmol/g) immediately after exposure (0 h) using the t-test for comparison. Levels of radioactivity in liver and kidney were higher than in blood for both rats and mice. Radioactivity retained in adrenal glands, thymus, and testes of mice was higher than in corresponding tissues in the rat. Levels of radioactivity were higher in all mouse tissues compared to rat tissues, with the exception of bone and fat. Differences between the species were most marked in the testes (3.5-fold higher levels of radioactivity in mice than rats). Blood levels of radioactivity decreased during the 42 h in metabolism cages to an equal level of 32 nmol/g in mice and 35 nmol/g in rats. At 42 h, higher levels of radioactivity were only seen in mouse liver and kidney, and not in mouse blood, using the t-test. No differences were seen between rat tissues and blood.
Autoradiography
Quantitative whole-body autoradiography of animals sacrificed 42 h after the termination of inhalation exposure were in good agreement with, and confirmed the results obtained by, combustion analyses of tissues (Table 3) . The values obtained for blood were approximately 33 nmol/g in mouse and 32 nmol/g in rat. The radioactivity measured in the majority of tissues was below that present in the blood and the quantitative distribution was similar in rats and mice. Residues in the liver, kidney cortex, thymus and nasal mucosa of mice were higher than blood. Residues in the liver, thymus, Harderian gland and preputial gland of rats were higher than blood.
Characterization and Identification of Urinary Metabolites
Analysis of urine collected from the Cannon exposure tower and from bladders (0 h) and 6, 24, and 42 h after termination of exposure indicated that the profile of metabolites in rats and mice was generally unchanged with time and between individual animals. Typical profiles of pooled urine from rats or mice are presented in Figures 4 and 5, respectively. Enzyme treatment with sulphatase or glucuronidase did not alter the chromatographic profiles, indicating that none of the metabolites were likely to be sulphates or glucuronides. Comparison of the metabolic profile before and after treatment of urine with acylase I (Tateishi, 1983) showed that most of the non-polar components (eluting after 8 min, Figs. 4 and 5) were mercapturic acids, the enzyme removing the N-acetyl group to produce the more polar cysteine conjugates. The chemical structures of metabolites were assigned by coelution with synthetic reference samples or fully characterized 14 C-metabolites (Richardson et al., 1998) and identification by LC/MS with online radioactivity monitoring. The identification of metabolites was facilitated by the high specific activity of the 14 C-butadiene (20 mCi/mmol), resulting in additional ions in the mass spectra corresponding to the presence of the two 14 C-labels (M ϩ 4). These unequivocally distinguished 14 C-butadiene metabolites from background signals.
Urinary Metabolites
HPLC analysis showed 4 major metabolites in rat and mouse urine eluting between 47-60 min (IIa, IIb, IIc, and IId, Figs. 4 and 5). These disappeared upon incubation with acylase with a concomitant increase in radioactivity recovered in the polar region of the chromatogram, which categorized them as mercapturic acids. Co-chromatography, with authentic reference standards and comparison of the elution times of metabolites in urine from rats and mice treated with 14 C-butadiene monoepoxide obtained under similar analytical conditions, identified IIa as (R)-2-(N-acetyl-L-cystein-S-yl)-1-hydroxybut-3-ene, (base peak), 174, 162, 130. The metabolites IIa and IIb arise from the reaction of GSH with (S)-butadiene monoepoxide and IIc and IId arise from the reaction of GSH with (R)-butadiene monoepoxide. The combined excretion of these metabolites accounted for 18.6 Ϯ 2.7% of radioactivity in rat urine and 16.7 Ϯ 0.7% in mouse urine, equivalent to 8% and 13% of metabolized butadiene (Table 4) in rats and mice respectively. The major isomer present in rat urine was IId, the C-1 regioisomer derived from (R)-butadiene monoepoxide (10.1 Ϯ 1.5%). The major isomer present in mouse urine was IIc, the C-2 isomer derived from (R)-butadiene monoepoxide (8.7 Ϯ 0.3%). The ratio of C-2 to C-1 metabolites was 3.2 Ϯ 0.7 in rats and 0.6 Ϯ 0.1 in mice. The R:S ratio of stereoisomers was 3.0 Ϯ 0.3 in rats and 2.8 Ϯ 0.4 in mice.
IIb as 1-(N-acetyl-L-cystein-S-yl)-2-(S)-hydroxybut-3-ene, IIc as 1-(N-acetyl-L-cystein-S-yl)-2-(R)-hydroxybut-3-ene and IId
as (S)-2-(N-acetyl-L-cystein-S-yl)-1-hydroxybut-3-ene (Richardson et al., 1998). Radio-LC/MS analysis of rat and mouse
Two major metabolites present in mouse urine eluting between 40 -50 min (IIf, IIg, Fig. 5) were not affected by any of the enzyme treatments, indicating that they were not sulphate, glucuronide, or mercapturic acid metabolites of 14 C-butadiene. Co-chromatography with metabolites isolated from mouse urine of mice treated with 14 C-butadiene monoepoxide identified them as S-(1-hydroxybut-3-ene-2-yl)-mercaptoacetic acid (IIf), S-(2-hydroxybut-3-ene-1-yl)-mercaptoacetic acid (IIg). Metabolites IIf and IIg accounted together for 5.4 Ϯ 0.6% of urinary radioactivity from the mouse (ϳ4% of metabolized butadiene). These metabolites were not present in rat urine. A major metabolite in both rat and mouse urine, eluted between 22-27 min (Ia, Figs. 4 and 5) and this disappeared upon incubation with acylase. This metabolite was identified as 4-(N-acetylcystein-S-yl)-1,2-dihydroxybutane (Ia) on the basis of coelution with a synthetic standard and comparison with urine from 14 C-butadiene monoepoxide-treated animals. LC/MS afforded a characteristic base peak at m/z: 252 (M ϩ H). GC/MS analysis of this metabolite, after derivatization by sequential methylation and acetylation, gave ions at m/z: EI 290 (M -59), 258, 230, 170, 155, 138, 117, 87, 71 , and 43 (base peak); CI(methane): 350 (M ϩ H). Metabolite Ia accounted for 17.5 Ϯ 2.9% of urinary radioactivity in rats and 10.1 Ϯ 0.5% in mice (ϳ7% of metabolized butadiene in both species).
In mouse urine, no other metabolites were identified in this region of the chromatogram. In rat urine, two closely eluting peaks (Ib and X) were seen in addition to Ia (Fig. 4) . These disappeared upon treatment with acylase, to produce radioactive peaks in the polar region of the chromatogram, which categorized them as mercapturic acids. Metabolite Ib co-chromatographed with 4-(N-acetylcystein-S-yl)-2-hydroxybutanoic acid identified in urine of rats treated with 14 C-butadiene monoepoxide . LC/MS analysis of Ib in rat urine afforded a characteristic base peak for this metabolite at m/z: 266 (M ϩ H). GC/MS analysis (Fig. 6 ) of this metabolite after derivatization by sequential methylation and acetylation gave ions at m/z: EI 335 (M ϩ. ), 276 (M -59), 244, 234, 202, 184, 128, 86, 68, and 43 (base peak) ; CI (methane): 336 (M ϩ H). Sufficient purified metabolite could not be obtained for detailed NMR analysis, but 1 H-NMR of isolated material was consistent with the proposed structure. Signals for an NAC moiety were clearly present. A signal at 2.65 ppm corresponded to CH 2 protons adjacent to a sulphur atom and the short-range coupling correlation indicated that this group was coupled to that with chemical shifts at 1.95/1.88. In addition, there was a signal at 4.1 ppm representing a single proton, assigned as the proton associated with the CH of the secondary ). Note: the small amount of sample available after isolation prevented a more detailed analysis of the NMR multiplets; coupling constants could not be obtained from spectrum.
The second metabolite (X), which was not observed in rat urine after treating rats with 14 C-butadiene monoepoxide , accounted for 9.3 Ϯ 1.8% of urinary radioactivity. Radio-LC/MS analysis afforded ions at m/z: 267 (M ϩ NH 4 ) , 250 (M ϩ H, base peak) (with associated M ϩ 4 ions at 271, and 254 respectively) and 164. LC/MS/MS (daughter ions of 250) yielded an ion at m/z: 250 (base peak, M ϩ H) and fragment ions at m/z: 164, 122, 119, 88, 87, and 57. The fragmentation pattern was consistent with a mercapturic acid with a molecular weight of 249. GC/MS analysis of the methyl derivative of this metabolite X, showed ions under EI conditions at m/z: 227/231, 216/220, 190/194, 178, 162, 158, 105, 88, 71 (base peak) , and from CI (methane) at m/z: 278/282 (M ϩ H). The mass spectra indicated that the molecular weight of the metabolite after methylation was 277. The molecular weight was consistent with the presence of two carboxyl moieties, with one originating from NAC, to give the corresponding dimethyl ester derivative. No change in the retention time or mass spectrum was observed after acetylation of the methylated metabolite. Comparison with the MS data of reference standards after derivatization by methylation showed that metabolite X was not 3-(N-acetylcystein-S-yl)-3-methylpropanoic acid, a potential urinary metabolite of butadiene derived from crotonaldehyde (Gray and Barnsley, 1971) or 3-(N-acetyl-L-cystein-S-yl)-2-oxopropanoic acid. It was not possible to obtain a completely homogeneous sample of X and although 1 H-NMR and proton coupled 1 H-13 C-NMR spectra were obtained, so far it has not been possible to unambiguously assign a structure to metabolite X which is unique to the rat.
Very small amounts of another metabolite identified as 4-(Nacetylcystein-S-yl)-2-ketobutanoic acid (Ie) was found in fractions isolated from rat urine containing metabolites Ia and Ib, after methylation. Radio-GC/MS afforded ions from EI at m/z: 291, 259, 227, 144, 114, 88, and 75 and from CI (methane) at m/z: 292 (M ϩ H) and associated M ϩ 4 ion at 296. No changes in the retention time or mass spectra were observed after acetylation of the methylated metabolite. LC/MS analysis confirmed the presence of a metabolite in rat urine with an ion at m/z: 264 (M ϩ H), and associated M ϩ 4 ion at 268.
3-(N-Acetylcystein-S-yl)-propan-1-ol and 3-(N-acetylcystein-S-yl)-propanoic acid, metabolites (Ic) and (Id) (Fig. 4) were identified only in rat urine by comparison with material from 14 C-butadiene monoepoxide treated rats, and these were not present in mouse urine. These metabolites disappeared upon incubation with acylase. LC/MS afforded a characteristic base peak at m/z: 236 (MϩH). Metabolites Ic and Id together accounted for 0.8 Ϯ 0.3% of urinary radioactivity (ϳ0.4% of metabolized butadiene).
Two metabolites eluting at ϳ7 and 8 min (IIIa and IIIb, Figs. 4 and 5) in both rat and mouse urine were characterized by treatment with acylase as mercapturic acids . LC/MS analysis yielded characteristic ions for both peaks at m/z: 268 (M ϩ H), with associated M ϩ 4 ion at 272 and 162. Co-chromatography with a reference standard identified metabolite IIIa as 4-(N-acetyl-L-cystein-S-yl)-1,2,3-trihydroxybutane. Metabolite IIIb was inferred to be the isomer 3-(N-acetyl-L-cystein- S-yl)-1,2,4-trihydroxybutane. IIIa and IIIb accounted together for 9.8 Ϯ 0.5% of urinary radioactivity (4.1 % of butadiene dose) in rats and 9.5% of urinary radioactivity (6.7% of butadiene dose) in mice.
LC/MS analysis indicated that the polar fraction of the chromatogram (3 to 8 min) contained a complex mixture of 14 C-metabolites. These accounted together for 39.8 Ϯ 1.5% of urinary radioactivity in rats and 46.7 Ϯ 0.8% in mice (equivalent to 17% and 33% of the exposure dose). LC/MS analysis for characteristic ions (at m/z: 250 and 130) identified some minor components eluting at 8.1 to 8.3 min as the sulphoxides of the isomeric metabolites 2-(N-acetyl-L-cystein-S-yl)-1-hydroxybut-3-ene and 1-(N-acetyl-L-cystein-S-yl)-2-hydroxybut-3-ene. Other components such as 1,2-dihydroxybut-3-ene, 1,3-dihydroxyacetone, 1,3-anhydroerythritol and erythritol were not detected.
DISCUSSION
This study has shown that male B6C3F1 mice and Sprague Dawley rats metabolize butadiene differently during and following a 6-h inhalation exposure to 200 ppm of [2,3-14 C]-butadiene. Furthermore, the elimination of radiolabelled metabolites and profiles of urinary metabolite were not the same as those observed following treatment of animals with a single ip dose of [4-
14 C]-butadiene monoepoxide (1-50 mg/kg), an established primary metabolite of butadiene .
The most striking difference between rats and mice in the metabolism of butadiene was in the proportions of radioactivity exhaled as CO 2 to that excreted in urine. In rats a large part of the butadiene was metabolized to 14 C-CO 2 (40%), the majority of this (70%) being exhaled during the actual exposure to butadiene. This was only a minor route (6%) for degradation of butadiene in mice. The largest proportion (42%) of the metabolized butadiene in mice was recovered in the urine in the first 6 h after cessation of exposure. In rats, the total urinary excretion accounted for 42% of metabolized butadiene and 71% in mice. For both rat and mouse, some radioactivity (8 -11%) was excreted in feces and some (9 -13%) remained in the carcass 42 h after cessation of the inhalation exposure. These findings show that 14 C-butadiene is rapidly metabolized in both species, but indicate major differences in the biotransformation of butadiene between rats and mice. In contrast to butadiene, no species differences in the elimination of radioactivity were observed when 14 C-butadiene monoepoxide was administered to rats and mice by ip injection .
Previous studies in rats and mice have measured 14 C-CO 2 exhalation only after cessation of a 6-h, nose-only inhalation exposure to butadiene (Bond et al., 1986) . For rats or mice, at all concentrations tested, both urine and exhaled air were the major routes of excretion of 14 C, and together accounted for 75-85% of the eliminated radioactivity. At most of the exposure concentrations, exhalation of CO 2 accounted for about 20% of the total 14 C eliminated or retained in the carcasses, cf. a study in the monkey where ϳ50% of radioactivity from an exposure to 10 ppm radiolabelled butadiene was exhaled as CO 2 (Dahl et al., 1990) . Since the degradation of butadiene and exhalation as CO 2 appeared to be a significant route of its elimination from rats and mice (Bond et al., 1986) , our present study also included analyses for CO 2 during the exposure period in order to better characterize this route of elimination. A comparison of results (Table 1 ) from this present study with data previously reported (Bond et al., 1986) indicates that the differences observed are due to the absence of data on the exhaled CO 2 during the exposure period in the earlier study. Our observation of very rapid excretion of radioactivity both in urine and as 14 C-CO 2 demonstrates the importance of acquiring metabolic data during the actual exposure period.
The total uptake of radioactivity from the inhalation exposures at a concentration of 200 ppm butadiene at 20 mCi/ mmole was 3796 Ci/kg and 7514 Ci/kg for rats and mice respectively (Table 1) . These values were equivalent to doses of 21 mg/kg butadiene in mice and 10 mg/kg butadiene in rats. Thus, on a unit-body-weight basis, when exposed to an air concentration of 200 ppm 14 C-butadiene, mice received approximately twice the dose of butadiene as rats. The higher dose in mice may, in part, account for the greater sensitivity of this species towards butadiene, but probably does not completely explain their extreme cancer susceptibility (6 ppm threshold) compared to rats (1000 ppm).
Similarly, radioactivity measured in blood and tissues was up to 3-fold higher in mice than rats immediately after cessation of exposure, and this was consistent with the greater absorbed dose (Ci/kg body weight) in mice (Table 2) . However, quantitative differences in the radioactivity measured in tissue did not correlate with the more than 100-fold difference in species sensitivity to cancer. This suggests that patterns of metabolites in tissues and the intrinsic sensitivity of individual tissues may also contribute to the carcinogenic outcome. Data has been published indicating that, following exposure of animals to butadiene, there were much higher concentrations of butadiene diepoxide in the blood of mice compared to rats (Himmelstein et al.,1994 (Himmelstein et al., , 1997 . Complete characterization of the profile of DNA adducts in the soft organs of exposed animals in the present study is in progress . The profiles of adducts can be used for both the qualitative and quantitative identification of reactive genotoxic metabolites in target tissue and may give further information on tissue specificity.
Analyses of metabolites in rat and mouse urine indicated that butadiene is extensively metabolized in both species. The urinary metabolic profiles in rats and mice are very similar (Figs. 4 and 5) and are also similar to those obtained from animals treated with 14 C-butadiene monoepoxide . The data from quantification of the metabolites is summarized in Table 4 . 1-(N-Acetylcystein-S-yl)-2-hydroxy-but-3-ene (C1 isomer, IIb and IIc) and 2-(N-acetylcystein-Syl)-1-hydroxybut-3-ene (C2 isomer, IIa and IId) accounted for 8% and 12% of the metabolized butadiene in rats and mice, respectively. These metabolites arise from the direct reaction of butadiene monoepoxide with glutathione (GSH) (Pathway I, Fig. 7 ). Nucleophilic substitution reactions by GSH at the C-1 or C-2 position of the epoxide, results in two diastereomeric pairs of regio-isomers, which are excreted in the urine as the corresponding mercapturic acids. As observed following treatment of animals with 14 C-butadiene monoepoxide, the excretion of the C-2 isomers, IIa and IId, predominated in rats (3:1), while the C-1 isomers, IIb and IIc, predominated in mice (2:1). This difference reflects the result of both the intrinsic and GSH-transferase-catalyzed reactions of GSH with butadiene monoepoxide. In rats exposed to butadiene, the ratio of reaction at C2/C1 was higher than after treatment with butadiene monoepoxide, which may be related to the in-situ formation of butadiene monoepoxide from butadiene, altering the balance between the intrinsic chemical and enzyme-catalyzed reactions.
In addition to regioselectivity, enantioselectivity was seen in the formation of these metabolites. The relative excretion of metabolites derived from (R)-or (S)-butadiene monoepoxide in the urine should reflect the formation of butadiene monoepoxide isomers from butadiene (Nieusma et al., 1997; Wistuba et al., 1989) as well as the affinity of enzymes involved in the further reactions of butadiene monoepoxide. After administration of a racemic mixture of 14 C-butadiene monoepoxide, metabolites originating from (R)-butadiene monoepoxide (IIc, IId) predominated (3:1) over those originating from (S)-butadiene monoepoxide (IIa, IIb) in both rats and mice . This was in agreement with the reported specificity of GSH-transferases for (R)-butadiene monoepoxide and epoxide hydrolases for (S)-butadiene monoepoxide (Wistuba and Schurig, 1986) . The findings in this present study with butadiene are similar, with metabolites IIc and IId arising from (R)-butadiene monoepoxide predominating. A second P450-dependent oxidation of butadiene monoepoxide to butadiene diepoxide in the mouse (Wistuba et al., 1989 ) also appears to be governed by stereochemical factors. (S)-butadiene monoepoxide is favored as a substrate for butadiene diepoxide formation, thus inducing further differences in the metabolism of butadiene between the species.
Mercaptoacetic acid metabolites (IIf and IIg) also found after treatment of animals with 14 C-butadiene monoepoxide were identified in mouse urine. These accounted for ϳ4% of the butadiene dose, indicating that in the mouse ϳ30% of the total flux through Pathway I (Fig. 7) is processed to mercaptoacetic acids compared to 70% as mercapturic acids.
An important pathway in the metabolism of butadiene in rats and mice, after oxidation of butadiene to butadiene monoepoxide, proceeds via hydrolysis to 1,2-dihydroxy-3-butene. 1,2-Dihydroxy-3-butene is oxidized to 1-hydroxybut-3-en-2-one, which reacts via Michael addition with GSH (Pathway II, Fig.  8 ). 1-Hydroxybut-3-en-2-one has been detected in in-vitro experiments (Kemper et al., 1997) . The resulting mercapturic acid, 4-(N-acetylcystein-S-yl)-1,2-dihydroxybutane (Ia), has been identified in the urine of hamsters, mice, rats and mon- keys and also humans occupationally exposed to butadiene (Bechtold et al., 1994; Nauhaus et al., 1996; Sabourin et al., 1992) . We recently identified 4-(N-acetylcystein-S-yl)-1,2-dihydroxybutane (Ia) as a major component in rat and mouse urine after treatment of animals with 14 C-butadiene monoepoxide, accounting for 5-8% and 3-5% of the dose, respectively . In the present study, the excretion of this metabolite accounted for 7% of the metabolized butadiene in both rats and mice.
Metabolites identified in rat, but not in mouse, urine after exposure to butadiene were 4-(N-acetylcystein-S-yl)-2-hydroxybutanoic acid (Ib, 1% of the butadiene dose), 3-(Nacetylcystein-S-yl)-propan-1-ol (Ic) and 3-(N-acetylcystein-Syl)-propanoic acid (Id). Ic and Id together accounted for ca. 1% of the butadiene dose. Since these metabolites were also present in rat urine after treatment with 14 C-butadiene monoepoxide (1-50 mg/kg) , we propose that they are derived from a common metabolic pathway (Pathway II, Fig. 8 ) through oxidation of 1,2-dihydroxy-3-butene, followed by reduction and decarboxylation steps. These metabolites may undergo transformation either as GSH-conjugates or as Co-A esters. The identification of the keto-acid (Ie) in trace quantities in rat urine further supports a pathway involving this type of intermediate.
An additional metabolite X (4% of butadiene dose), not present in urine after treatment with 14 C-butadiene monoepoxide , was observed in rat, but in not mouse urine after exposure to butadiene, but it could not be identified. Comparison with reference standards showed that X was not 3-(N-acetylcystein-S-yl)-3-methylpropanoic acid, a urinary metabolite of crotonaldehyde (Gray and Barnsley, 1971) , or 3-(N-acetylcystein-S-yl)-2-oxopropanoic acid, a potential candidate structure based on a molecular weight of 249. However, this unidentified metabolite (X) was only observed in the rat, like the findings for 3-(N-acetylcystein-S-yl)-propan-1-ol (Ic) and 3-(N-acetylcystein-S-yl)-propanoic acid (Id). It seems unlikely therefore that X is a product in a pathway that contributes significantly to the toxicity of butadiene.
The isomers of the N-acetylcystein-S-yl-trihydroxybutane (IIIa and IIIb) were identified in the urine of both rats and mice after exposure to butadiene. Approximately twice as much of these metabolites were found in mouse urine as in rat urine (4% and 7% of the butadiene dose in rat and in mouse, respectively). These metabolites can be formed from the reaction of GSH with either 1,2-dihydroxy-3,4-epoxybutane or butadiene diepoxide (Pathway III, Fig. 9 ). The former reaction pathway is likely to predominate in the rat, since butadiene diepoxide is not a significant metabolite in rat blood (ThorntonManning et al., 1995b) , possibly because the diepoxide could be hydrolyzed to 1,2-dihydroxy-3,4-epoxybutane. It is probable that both of the butadiene metabolites are responsible for the formation of this conjugate in the mouse, since butadiene diepoxide is an established metabolite of butadiene in mouse in-vivo (Himmelstein et al., 1994; Thornton-Manning et al., 1995a) . The trihydroxybutyl mercapturic acids IIIa and IIIb and other potential metabolites of butadiene diepoxide, could not be detected in urine of rats or mice treated with butadiene monoepoxide . These results suggest that butadiene monoepoxide is not an effective intermediate in the formation of either 1,2-dihydroxy-3,4-epoxy-butane or butadiene diepoxide when administered by ip injection and imply that the formation of butadiene monoepoxide in situ from butadiene is important in determining further oxidation. The mechanism of formation of 1,2-dihydroxy-3,4-epoxy-butane in mouse or rat is, however, still uncertain. One possibility involves the formation of 1,2-dihydroxy-3,4-epoxy-butane via oxidation of 1,2-dihydroxy-3-butene (Fig. 9 , Pathway III). However, this seems unlikely because similar amounts (as a proportion of dose) of 1,2-dihydroxy-3-butene were present in the urine samples from both studies. In addition, as noted above, no trihydroxybutyl mercapturates were observed in our metabolism study with butadiene monoepoxide . An alternative explanation is that 1,2-hydroxy-3,4-epoxybutane is derived from butadiene diepoxide but enzymic hydrolysis of the diepoxide prevents it from being a significant metabolite in rat blood.
Comparison of our metabolic data for butadiene monoepoxide with results from the present study suggests that the oxidation of butadiene to butadiene diepoxide may occur without release of the intermediate butadiene monoepoxide from the proximity of the oxidizing P450. It appears that once released from the enzyme butadiene monoepoxide is less effective as an intermediate for the formation of butadiene diepoxide, since it can be hydrolyzed by epoxide hydrolases or react with GSH before diffusion into the P450 active site for a second oxidation . Recently, modelling of cytochrome P450 (CYP2E1) showed that differences in the active site between mouse and rat CYP2E1 may determine the probability of the second oxidation to butadiene diepoxide (Lewis et al., 1997) . ThorntonManning et al. (1996) has shown that there is no linear correlation between blood and tissue levels of butadiene monoepoxide and diepoxide in rats or mice. In rats, the levels of the diepoxide were very low and did not increase with increasing exposure concentration of butadiene, although butadiene monoepoxide levels increased. In mice, levels of butadiene diepoxide up to 10 times higher than those of butadiene monoepoxide were measured at low butadiene exposures, whereas levels of the diepoxide 2 to 3 times lower than butadiene monoepoxide levels were seen at higher butadiene exposures.
The precise pathway in the rat for forming 14 C-CO 2 from butadiene is not presently known, but, because the rat is less sensitive to butadiene carcinogenicity, the formation of the large amount of CO 2 in this species probably occurs through non-toxic intermediates. The position of the radiolabel in the [2,3-14 C]-butadiene was selected to determine whether the 14 C-CO 2 came from the loss of a terminal carbon atom of butadiene as a carboxyl group (Dahl et al., 1990) , and was thus part of a pathway that produced the 3-carbon metabolites 1c and 1d. With the carbon-14 label at positions 2 and 3, no 14 C-CO 2 would be expected for a single carbon loss, but the resulting metabolites would be detected in the urine. Therefore, formation of 14 C-CO 2 in this study is the result of loss of two (or more) carbon atoms from butadiene. In a previous study using [1-
14 C]-butadiene, 14 C-CO 2 was also measured as a significant metabolite (Bond et al., 1986) . Both labelling approaches therefore underestimate the amount of degradation of butadiene to CO 2 . Measurements to determine exhaled 14 C-CO 2 were not made in our metabolism study with 14 C-butadiene monoepoxide , but the results from that study show that there was no overall difference in recoveries of radioactivity between rats and mice. This would not have been the case if substantial metabolism of 14 C-butadiene monoepoxide to 14 CO 2 had occurred in rats. This in turn implies that the metabolic pathways observed in the 14 C-butadiene monoepoxide study were not the major source of CO 2 in rat but cannot be ruled out as a source of CO 2 in the mouse. Metabolism of butadiene diepoxide in rat may lead to the formation of 14 C-CO 2 . The trihydroxybutyl mercapturates, which could form from butadiene diepoxide, were not observed after exposure of animals to butadiene monoepoxide. Another source of CO 2 may be associated with the formation of unidentified metabolite X, found in rat urine after butadiene exposure but not from butadiene monoepoxide.
In conclusion, the results from this study show that species differences in the metabolism of butadiene are not simply confined to the quantitative formation of epoxides but also indicate a different selection of metabolic pathways. Factors such as the catabolism of primary metabolites and the selective formation of stereoisomers may govern the flux through these pathways. A major proportion of the metabolized butadiene in rats is exhaled as CO 2 . Metabolism of butadiene to CO 2 also occurs in mice but the exposure-elimination profile is significantly different from that observed in rats. The mechanism of formation of CO 2 from butadiene is still not known in either species. Comparison of data from treatments of animals with butadiene or butadiene monoepoxide suggests that butadiene monoepoxide itself in blood is not effective for the formation of butadiene diepoxide. The exact mechanism of formation of butadiene diepoxide from butadiene is not known, but our evidence suggests that its formation may be a concerted process occurring without the intermediate monoepoxide leaving the vicinity of the metabolising enzyme. These oxidative pathways are clearly of critical importance in the metabolism of butadiene, because metabolites other than those derived from epoxidation of butadiene were not identified in the urine of rats or mice after exposure to 14 C-butadiene.
APPENDIX
Abbreviations
Butadiene, 1,3-butadiene; butadiene diepoxide, 1,2,3,4-diepoxybutane; butadiene monoepoxide, 1,2-epoxy-3-butene; BSTFA, bis-silyl trifluoroacetamide; DMSO, dimethyl sulphoxide; HMPA, hexamethylphosphoramide; NAC, N-acetylcysteine; NOEL, no observed effect level; sa, specific radioactivity; PBPK, physiologically based pharma- 
